ASCO 2022: Immediate Options for Endocrine Therapy–Refractory Patients With HER2-Low Metastatic Breast Cancer

Tarah J. Ballinger, MD


June 23, 2022

Tarah J. Ballinger, MD, conveys the immediate impact that the results from the DESTINY-Breast04 trial will have on her patients with triple-negative and hormone-refractory metastatic breast cancer.

The results of the trial lead Dr Ballinger to think about a specific patient who is now classified as having HER2-low disease, thus allowing her to tap the potential for better quality of life with the option of trastuzumab deruxtecan.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.